Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 08, 2026 | May 09, 2026 |
| Envista Holdings CorpNVST · Entity 4007 | Director | May 19, 2026 | May 21, 2026 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director | May 13, 2022 | May 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 08, 2026 · Filed May 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,315 |
Ending reported balance
After 2026-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-08 · Grant · Acquired 3,251 · Balance 3,251 F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Row 2 · 2026-05-08 · Grant · Acquired 1,064 · Balance 4,315 F2: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 79,656 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 79,656 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
F2: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
Envista Holdings Corp
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,010 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 9,330 · Balance 54,010 F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an annual equity grant of Restricted Stock Units ("RSUs") for the Reporting Person's service as a director of the Issuer. The RSUs will vest on the first anniversary of the grant date. RSUs are payable in shares of common stock on a one-to-one basis.
Intersect ENT, Inc.
Report date May 13, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-13 · Other · Disposed 3,239 · Balance 5,011 F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Row 2 · 2022-05-13 · Other · Disposed 5,011 · Balance 0 F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-05-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-05-13 · Other · Disposed 29,262 · Balance 0 F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. F3: The reportable securities are held by the Gallahue Irrevocable Trust. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.10 · Expires 2029-05-06 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-13 · Other · Disposed 120,064 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2031-03-15 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-13 · Other · Disposed 3,390 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.01 · Expires 2029-09-29 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-13 · Other · Disposed 82,387 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.50 · Expires 2031-06-02 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-13 · Other · Disposed 5,734 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.79 · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.84 · Expires 2030-06-03 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-13 · Other · Disposed 9,666 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.05 · Expires 2028-06-04 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-13 · Other · Disposed 3,473 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-13 · Other · Disposed 6,035 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.31 · Expires 2025-04-07 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-05-13 · Other · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-05-13 · Other · Disposed 13,248 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].
F3: The reportable securities are held by the Gallahue Irrevocable Trust.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARENA PHARMACEUTICALS INC
Report date March 11, 2022 · Filed March 11, 2022
Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Gallahue Irrevocable Trust | 0 |
Reported balance
After 2022-03-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-03-11 · Other · Disposed 3,628 · Balance 0 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-11 transaction · row 3
2 source rows · reconciled sequenceRow 2 · 2022-03-11 · Other · Disposed 1,116 · Balance 8,167 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Row 3 · 2022-03-11 · Other · Disposed 8,167 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.79 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-11 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.79 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-11 · Disposition to issuer · Disposed 4,583 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.19 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Disposition to issuer · Disposed 7,202 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2021 Filed May 7, 2021 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007755 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,615 F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 19:32 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (right to buy) · Derivative | 3,390 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002360 · primarydocument.xml · derivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,390 Underlying: Common Stock · 3,390 shares Expires 2031-03-15 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2021. Read SEC document |
| December 21, 2020 Filed Feb 16, 2021 18:18 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GiftCommon Stock | 3,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010950 · doc5.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,216 F1 · shares: On December 21, 2020, the Reporting Person transferred 3,628 shares of the Issuer's common stock to a family trust of which the Reporting Person is a trustee. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:42 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $61.31 | $0.00 |
DisclosureSEC source: 0001209191-20-037104 · doc4.xml · derivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-12 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:42 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 2,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037104 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,844 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:49 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (right to buy) · Derivative | 9,666 | $0.00 Strike: $11.84 | $0.00 |
DisclosureSEC source: 0001562180-20-004315 · primarydocument.xml · derivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,666 Underlying: Common Stock · 9,666 shares Expires 2030-06-03 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:49 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 5,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004315 · primarydocument.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,273 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021. F2 · balance_after: Includes 5,011 restricted stock units. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:21 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantRestricted Stock Unit · Derivative | 8,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001372 · form4-05292020_010531.xml · derivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,230 Underlying: Common Stock · 8,230 shares Expires 2030-05-26 F1 · derivative.exercise_price: Restricted stock units are payable in shares of common stock on a one-to-one basis. F2 · derivative.exercise_date: The restricted stock units granted will vest on the date of the Issuer's 2021 annual meeting of stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the issuer. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 345 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 3 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,446 F2 · shares: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101 F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 07, 2020 Filed May 11, 2020 18:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 1,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 4 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 17,471 Read SEC document |
| May 07, 2020 Filed May 11, 2020 18:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 1,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 22:34 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 2,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029795 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,035 F1 · shares: Award of restricted stock units under the Envista Holdings Corporation 2019 Omnibus Incentive Plan, which will vest on the earlier to occur of the first anniversary of the date of grant or the date of the Issuer's 2020 annual meeting of stockholders, subject to continued service through such date. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:09 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (right to buy) · Derivative | 82,387 | $0.00 Strike: $17.01 | $0.00 |
DisclosureSEC source: 0001562180-19-005068 · primarydocument.xml · derivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,387 Underlying: Common Stock · 82,387 shares Expires 2029-09-29 F3 · derivative.exercise_date: 1/8 of the shares subject to the option vest on September 30, 2019 and 1/8th of the shares subject to the option vests monthly on the last business day of the month thereafter over seven (7) successive months. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:09 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 17,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-005068 · primarydocument.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,262 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. 100% of the restricted stock units shall vest on April 30, 2020. F2 · balance_after: Includes 17,202 restricted stock units. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 18:43 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $56.50 | $0.00 |
DisclosureSEC source: 0001209191-19-037490 · doc4.xml · derivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-13 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 18:43 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 2,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037490 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,398 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007857 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,737 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007857 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,323 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| May 07, 2019 Filed May 8, 2019 18:45 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (right to buy) · Derivative | 180,096 | $0.00 Strike: $25.10 | $0.00 |
DisclosureSEC source: 0001562180-19-002724 · primarydocument.xml · derivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,096 Underlying: Common Stock · 180,096 shares Expires 2029-05-06 F1 · derivative.exercise_date: The shares subject to the option vest in six equal monthly installments commencing on May 31, 2019. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 16:14 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 4,583 | $0.00 Strike: $44.79 | $0.00 |
DisclosureSEC source: 0001209191-18-042143 · doc4.xml · derivative · entry 4 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,583 Underlying: Common Stock · 4,583 shares Expires 2025-07-06 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on August 6, 2018, and are exercisable once vested. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 16:14 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $44.79 | $0.00 |
DisclosureSEC source: 0001209191-18-042143 · doc4.xml · derivative · entry 3 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-07-06 F3 · derivative.exercise_date: The options vest in 36 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over three years beginning on August 6, 2018, and are exercisable once vested. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 16:14 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 3,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042143 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,744 F2 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 16:14 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 1,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042143 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,674 F1 · shares: The amount represents restricted stock units that vest in three equal installments on the dates of Arena's next three annual meetings of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 17:20 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 3,473 | $0.00 Strike: $42.05 | $0.00 |
DisclosureSEC source: 0001562180-18-002920 · primarydocument.xml · derivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473 Underlying: Common Stock · 3,473 shares Expires 2028-06-04 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 5, 2018. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 17:20 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 1,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002920 · primarydocument.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,060 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 5, 2019. F2 · balance_after: Includes 1,514 RSUs. Read SEC document |
| May 18, 2018 Filed May 23, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 479 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009759 · doc4.xml · nonDerivative · entry 3 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,134 F2 · shares: This restricted stock was granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. Read SEC document |
| May 18, 2018 Filed May 23, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009759 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,655 F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board. Read SEC document |
| May 12, 2018 Filed May 23, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 2,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009759 · doc4.xml · nonDerivative · entry 4 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 13,600 Read SEC document |
| May 12, 2018 Filed May 23, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 2,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009759 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 19:29 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 6,035 | $0.00 Strike: $26.05 | $0.00 |
DisclosureSEC source: 0001562180-17-002197 · primarydocument.xml · derivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 Underlying: Common Stock · 6,035 shares Expires 2027-05-31 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 19:29 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002197 · primarydocument.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,546 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantDirector Stock Option (Right to Acquire) · Derivative | 2,352 | $0.00 Strike: $110.59 | $0.00 |
DisclosureSEC source: 0001225208-17-009784 · doc4.xml · derivative · entry 3 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,352 Underlying: Common Stock · 2,352 shares Expires 2024-05-11 F3 · derivative.exercise_date: These options were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date. F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009784 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,034 F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it reflects 2,524 shares that were previously reported as directly held. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | PurchaseCommon Stock | 3,000 | $90.10 | $270,300.00 |
DisclosureSEC source: 0001225208-17-002461 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 9,042 Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 19:36 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 13,248 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001562180-17-000293 · primarydocument.xml · derivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,248 Underlying: Common Stock · 13,248 shares Expires 2027-01-17 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2017. Read SEC document |
| November 29, 2016 Filed Dec 2, 2016 00:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | PurchaseCommon Stock | 3,000 | $84.63 | $253,900.20 |
DisclosureSEC source: 0001225208-16-042548 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,042 F1 · price: This transaction was executed in multiple trades at prices ranging from $84.38 to $84.98. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Reflects a difference of 3,042 shares which were previously reported as directly held by the Reporting Person but are held by Trust. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.